Full Text:   <1727>

Summary:  <597>

CLC number: R575

On-line Access: 2016-11-03

Received: 2016-03-03

Revision Accepted: 2016-05-14

Crosschecked: 2016-10-10

Cited: 6

Clicked: 2788

Citations:  Bibtex RefMan EndNote GB/T7714


Yang Guo


-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2016 Vol.17 No.11 P.831-841


Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis

Author(s):  Yang Guo, Bo Chen, Li-jun Chen, Chun-feng Zhang, Charlie Xiang

Affiliation(s):  State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China

Corresponding email(s):   mavis199005@zju.edu.cn, cxiang@zju.edu.cn

Key Words:  Liver fibrosis, Cell therapy, Mesenchymal stem cells

Yang Guo, Bo Chen, Li-jun Chen, Chun-feng Zhang, Charlie Xiang. Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis[J]. Journal of Zhejiang University Science B, 2016, 17(11): 831-841.

@article{title="Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis",
author="Yang Guo, Bo Chen, Li-jun Chen, Chun-feng Zhang, Charlie Xiang",
journal="Journal of Zhejiang University Science B",
publisher="Zhejiang University Press & Springer",

%0 Journal Article
%T Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis
%A Yang Guo
%A Bo Chen
%A Li-jun Chen
%A Chun-feng Zhang
%A Charlie Xiang
%J Journal of Zhejiang University SCIENCE B
%V 17
%N 11
%P 831-841
%@ 1673-1581
%D 2016
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1600101

T1 - Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis
A1 - Yang Guo
A1 - Bo Chen
A1 - Li-jun Chen
A1 - Chun-feng Zhang
A1 - Charlie Xiang
J0 - Journal of Zhejiang University Science B
VL - 17
IS - 11
SP - 831
EP - 841
%@ 1673-1581
Y1 - 2016
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1600101

liver fibrosis is the end-stage of many chronic liver diseases and is a significant health threat. The only effective therapy is liver transplantation, which still has many problems, including the lack of donor sources, immunological rejection, and high surgery costs, among others. However, the use of cell therapy is becoming more prevalent, and mesenchymal stem cells (MSCs) seem to be a promising cell type for the treatment of liver fibrosis. MSCs have multiple differentiation abilities, allowing them to migrate directly into injured tissue and differentiate into hepatocyte-like cells. Additionally, MSCs can release various growth factors and cytokines to increase hepatocyte regeneration, regress liver fibrosis, and regulate inflammation and immune responses. In this review, we summarize the current uses of MSC therapies for liver fibrosis and suggest potential future applications.



Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article


[1]Aggarwal, S., Pittenger, M.F., 2005. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4):1815-1822.

[2]Arthur, M.J., 1995. Collagenases and liver fibrosis. J. Hepatol., 22(2 Suppl.):43-48.

[3]Arthur, M.J., 1997. Matrix degradation in liver: a role in injury and repair. Hepatology, 26(4):1069-1071.

[4]Banas, A., Teratani, T., Yamamoto, Y., et al., 2007. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology, 46(1):219-228.

[5]Benyon, R.C., Iredale, J.P., Goddard, S., et al., 1996. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology, 110(3):821-831.

[6]Berardis, S., Dwisthi Sattwika, P., Najimi, M., et al., 2015. Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. World J. Gastroenterol., 21(3):742-758.

[7]Bӧker, K.H., Pehle, B., Steinmetz, C., et al., 2000. Tissue inhibitors of metalloproteinases in liver and serum/plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogastroenterology, 47(33):812-819.

[8]Bonefeld, K., Møller, S., 2011. Insulin-like growth factor-I and the liver. Liver Int., 31(7):911-919.

[9]Campagnoli, C., Roberts, I.A., Kumar, S., et al., 2001. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood, 98(8):2396-2402.

[10]Campard, D., Lysy, P.A., Najimi, M., et al., 2008. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology, 134(3):833-848.

[11]Chan, T.M., Harn, H.J., Lin, H.P., et al., 2014. Improved human mesenchymal stem cell isolation. Cell Transplant., 23(4-5):399-406.

[12]Corcione, A., Benvenuto, F., Ferretti, E., et al., 2006. Human mesenchymal stem cells modulate B-cell functions. Blood, 107(1):367-372.

[13]de Ugarte, D.A., Morizono, K., Elbarbary, A., et al., 2003. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs, 174(3):101-109.

[14]di Nicola, M., Carlo-Stella, C., Magni, M., et al., 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99(10):3838-3843.

[15]Ek, M., Soderdahl, T., Küppers-Munther, B., et al., 2007. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem. Pharmacol., 74(3):496-503.

[16]Eom, Y.W., Kim, G., Baik, S.K., 2015. Mesenchymal stem cell therapy for cirrhosis: present and future perspectives. World J. Gastroenterol., 21(36):10253-10261.

[17]Erices, A., Conget, P., Minguell, J.J., 2000. Mesenchymal progenitor cells in human umbilical cord blood. Br. J. Haematol., 109(1):235-242.

[18]Fiore, E.J., Bayo, J.M., Garcia, M.G., et al., 2015. Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice. Stem Cells Dev., 24(6):791-801.

[19]Forbes, S.J., Russo, F.P., Rey, V., et al., 2004. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology, 126(4):955-963.

[20]Friedland, A.E., Tzur, Y.B., Esvelt, K.M., et al., 2013. Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat. Methods, 10(8):741-743.

[21]Friedman, S.L., 1993. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med., 328(25):1828-1835.

[22]Glennie, S., Soeiro, I., Dyson, P.J., et al., 2005. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood, 105(7):2821-2827.

[23]Golzar, F., Javanmard, S.H., Bahrambeigi, V., et al., 2015. The effect of Kisspeptin-10 on mesenchymal stem cells migration in vitro and in vivo. Adv. Biomed. Res., 4:20.

[24]Gratz, S.J., Cummings, A.M., Nguyen, J.N., et al., 2013. Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics, 194(4):1029-1035.

[25]Groh, M.E., Maitra, B., Szekely, E., et al., 2005. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol., 33(8):928-934.

[26]Hang, H., Yu, Y., Wu, N., et al., 2014. Induction of highly functional hepatocytes from human umbilical cord mesenchymal stem cells by HNF4α transduction. PLOS ONE, 9(8):e104133.

[27]Hay, E.D., 2005. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev. Dyn., 233(3):706-720.

[28]Hengstler, J.G., Brulport, M., Schormann, W., et al., 2005. Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin. Drug Metab. Toxicol., 1(1):61-74.

[29]Hruscha, A., Krawitz, P., Rechenberg, A., et al., 2013. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development, 140(24):4982-4987.

[30]Huang, X., Liu, L.I., Liu, N., 2015. Molecular mechanism of tumor necrosis factor-alpha monoclonal antibody in hepatopulmonary syndrome in rats. Chin. J. Hepatol., 23(6):458-463 (in Chinese).

[31]Iredale, J.P., Murphy, G., Hembry, R.M., et al., 1992. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J. Clin. Invest., 90(1):282-287.

[32]Ishii, K., Yoshida, Y., Akechi, Y., et al., 2008. Hepatic differentiation of human bone marrow-derived mesenchymal stem cells by tetracycline-regulated hepatocyte nuclear factor 3β. Hepatology, 48(2):597-606.

[33]Jang, Y.O., Kim, M.Y., Cho, M.Y., et al., 2014. Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model. BMC Gastroenterol., 14(1):198.

[34]Jiang, W.Y., Bikard, D., Cox, D., et al., 2013. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol., 31(3):233-239.

[35]Jiang, X.X., Zhang, Y., Liu, B., et al., 2005. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105(10):4120-4126.

[36]Jiang, Y.H., Vaessen, B., Lenvik, T., et al., 2002. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp. Hematol., 30(8):896-904.

[37]Kakinuma, S., Nakauchi, H., Watanabe, M., 2009. Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. J. Gastroenterol., 44(3):167-172.

[38]Kelly, J.D., Haldeman, B.A., Grant, F.J., et al., 1991. Platelet-derived growth factor (PDGF) stimulates PDGF receptor subunit dimerization and intersubunit trans-phosphorylation. J. Biol. Chem., 266(14):8987-8992.

[39]Kharaziha, P., Hellstrom, P.M., Noorinayer, B., et al., 2009. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I‒II clinical trial. Eur. J. Gastroenterol. Hepatol., 21(10):1199-1205.

[40]Kim, M.D., Kim, S.S., Cha, H.Y., et al., 2014. Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis. Exp. Mol. Med., 46:e110.

[41]Kiss, J., Urbán, V.S., Dudics, V., et al., 2008. Mesenchymal stem cells and the immune system—immunosuppression without drugs? Orv. Hetil., 149(8):339-346 (in Hungarian).

[42]Krampera, M., Glennie, S., Dyson, J., et al., 2003. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101(9):3722-3729.

[43]Krampera, M., Cosmi, L., Angeli, R., et al., 2006. Role for interferon-γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2):386-398.

[44]Lian, G.W., Wang, C.Y., Teng, C.B., et al., 2006. Failure of hepatocyte marker-expressing hematopoietic progenitor cells to efficiently convert into hepatocytes in vitro. Exp. Hematol., 34(3):348-358.

[45]Lichtinghagen, R., Michels, D., Haberkorn, C.I., et al., 2001. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J. Hepatol., 34(2):239-247.

[46]Lin, H., Xu, R., Zhang, Z., et al., 2011. Implications of the immunoregulatory functions of mesenchymal stem cells in the treatment of human liver diseases. Cell. Mol. Immunol., 8(1):19-22.

[47]Liu, W.H., Song, F.Q., Ren, L.N., et al., 2015. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J. Cell. Mol. Med., 19(3):511-520.

[48]Liu, Y., Zuo, G.Q., Zhao, L., et al., 2013. Effect of inflammatory stress on hepatic cholesterol accumulation and hepatic fibrosis in C57BL/6J mice. Chin. J. Hepatol., 21(2):116-120 (in Chinese).

[49]Lourenco, S., Teixeira, V.H., Kalber, T., et al., 2015. Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J. Immunol., 194(7):3463-3474.

[50]Mandal, P.K., Ferreira, L.M., Collins, R., et al., 2014. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell, 15(5):643-652.

[51]Meisel, R., Zibert, A., Laryea, M., et al., 2004. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103(12):4619-4621.

[52]Milani, S., Herbst, H., Schuppan, D., et al., 1994. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am. J. Pathol., 144(3):528-537.

[53]Mohsin, S., Shams, S., Ali Nasir, G., et al., 2011. Enhanced hepatic differentiation of mesenchymal stem cells after pretreatment with injured liver tissue. Differentiation, 81(1):42-48.

[54]Mou, X.Z., Lin, J., Chen, J.Y., et al., 2013. Menstrual blood-derived mesenchymal stem cells differentiate into functional hepatocyte-like cells. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 14(11):961-972.

[55]Nauta, A.J., Kruisselbrink, A.B., Lurvink, E., et al., 2006. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol., 177(4):2080-2087.

[56]Ortiz, L.A., DuTreil, M., Fattman, C., et al., 2007. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. PNAS, 104(26):11002-11007.

[57]Parekkadan, B., van Poll, D., Megeed, Z., et al., 2007. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem. Biophys. Res. Commun., 363(2):247-252.

[58]Potian, J.A., Aviv, H., Ponzio, N.M., et al., 2003. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol., 171(7):3426-3434.

[59]Puglisi, M.A., Tesori, V., Lattanzi, W., et al., 2011. Therapeutic implications of mesenchymal stem cells in liver injury. J. Biomed. Biotechnol., 2011:860578.

[60]Rasmusson, I., Ringdén, O., Sundberg, B., et al., 2003. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76(8):1208-1213.

[61]Reinders, M.E., Rabelink, T.J., de Fijter, J.W., 2013. The role of mesenchymal stromal cells in chronic transplant rejection after solid organ transplantation. Curr. Opin. Organ Transplant., 18(1):44-50.

[62]Schmidt, T., Schmid-Burgk, J.L., Hornung, V., 2015. Synthesis of an arrayed sgRNA library targeting the human genome. Sci. Rep., 5:14987.

[63]Seah, Y.F.S., el Farran, C.A., Warrier, T., et al., 2015. Induced pluripotency and gene editing in disease modelling: perspectives and challenges. Int. J. Mol. Sci., 16(12):28614-28634.

[64]Sharma, R.R., Pollock, K., Hubel, A., et al., 2014. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion, 54(5):1418-1437.

[65]Shi, M., Liu, Z.W., Wang, F.S., 2011. Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin. Exp. Immunol., 164(1):1-8.

[66]Siller-López, F., Sandoval, A., Salgado, S., et al., 2004. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology, 126(4):1122-1133; discussion 1949.

[67]Snykers, S., Vanhaecke, T., de Becker, A., et al., 2007. Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. BMC Dev. Biol., 7:24.

[68]Sotiropoulou, P.A., Perez, S.A., Gritzapis, A.D., et al., 2006. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24(1):74-85.

[69]Tse, W.T., Pendleton, J.D., Beyer, W.M., et al., 2003. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 75(3):389-397.

[70]Wang, H., Yang, H., Shivalila, C.S., et al., 2013. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell, 153(4):910-918.

[71]Wang, Y., Li, Z., Xu, J., et al., 2013. The CRISPR/Cas system mediates efficient genome engineering in Bombyx mori. Cell Res., 23(12):1414-1416.

[72]Wells, R.G., Kruglov, E., Dranoff, J.A., 2004. Autocrine release of TGF-β by portal fibroblasts regulates cell growth. FEBS Lett., 559(1-3):107-110.

[73]Wettstein, R., Bodak, M., Ciaudo, C., 2016. Generation of a knockout mouse embryonic stem cell line using a paired CRISPR/Cas9 genome engineering tool. Methods Mol. Biol., 1341:321-343.

[74]Wrana, J.L., 1999. Transforming growth factor-β signaling and cirrhosis. Hepatology, 29(6):1909-1910.

[75]Yin, L.B., Zhu, Y.H., Yang, J.G., et al., 2015. Adipose tissue-derived mesenchymal stem cells differentiated into hepatocyte-like cells in vivo and in vitro. Mol. Med. Rep., 11(3):1722-1732.

[76]Yoshida, Y., Shimomura, T., Sakabe, T., et al., 2007. A role of Wnt/β-catenin signals in hepatic fate specification of human umbilical cord blood-derived mesenchymal stem cells. Am. J. Physiol. Gastrointest. Liver Physiol., 293(5):G1089-G1098.

[77]Zappia, E., Casazza, S., Pedemonte, E., et al., 2005. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 106(5):1755-1761.

[78]Zhang, F., Wen, Y., Guo, X., 2014. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum. Mol. Genet., 23(R1):R40-R46.

[79]Zhang, W., Ge, W., Li, C.H., et al., 2004. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev., 13(3):263-271.

[80]Zhou, P., Hohm, S., Olusanya, Y., et al., 2009. Human progenitor cells with high aldehyde dehydrogenase activity efficiently engraft into damaged liver in a novel model. Hepatology, 49(6):1992-2000.

Open peer comments: Debate/Discuss/Question/Opinion


Please provide your name, email address and a comment

Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE